Leadership Team

Trovagene is a clinical-stage oncology therapeutics company. Our primary focus is to develop targeted therapeutics for improved cancer care utilizing our expertise and technology in tumor genomics to optimize drug development and to help identify patients most likely to respond. Our dedicated team give their time and energy for something they truly value and in turn we are striving to develop new cancer therapeutics in areas of significant medical need, such as Acute Myeloid Leukemia (AML) and metastatic Castration-Resistant Prostate Cancer (mCRPC). It is through our passion and desire to transform cancer care that we have embarked on a journey to develop our lead drug candidate, PCM-075, the only highly-selective, orally administered, Polo-like Kinase 1 (PLK1) Inhibitor in clinical development to treat various hematologic and solid tumor cancers.

Board of Directors

Thomas Adams, PhD

Interim CEO & Chairman of the Board